Showing 41 - 60 results of 81,645 for search '(( 6 0 decrease ) OR ( 50 ((we decrease) OR (((mean decrease) OR (a decrease)))) ))', query time: 1.50s Refine Results
  1. 41

    Expression of neurotrophins and their receptors was decreased in <i>Slitrk6</i>-deficient inner ear. by Kei-ichi Katayama (257931)

    Published 2009
    “…The graphs depict mean + SD of 3 independent analyses. The mRNAs of <i>Bdnf</i> and <i>Ntf3</i> were significantly decreased in <i>Slitrk6</i>-deficient inner ear, whereas those of <i>Ntrk2</i> and <i>Ntrk3</i> were not. * <i>p</i><0.05, Student's <i>t</i>-test. …”
  2. 42

    Zebrafish harboring homozygous mutations in <i>gdf6</i> exhibit decreased endurance. by Michèle G. DuVal (278183)

    Published 2014
    “…<i>gdf6<sup>−/−</sup></i> fish have approximately 50% lower endurance compared to <i>gdf6<sup>+/+</sup></i> siblings at each age (*p = 0.005, **p<0.01). …”
  3. 43
  4. 44

    Image_1_Decrease in Serum Urate Level Is Associated With Loss of Visceral Fat in Male Gout Patients.tif by Zijing Ran (11429935)

    Published 2021
    “…</p>Results<p>ULT resulted in a mean (standard deviation) decrease in SU level (464.22 ± 110.21 μmol/L at baseline, 360.93 ± 91.66 μmol/L at the final visit, p <0.001) accompanied by a decrease in median (interquartile range) VFA [97.30 (81.15–118.55) at baseline, 90.90 (75.85–110.05) at the final visit, p < 0.001]. …”
  5. 45
  6. 46
  7. 47
  8. 48
  9. 49
  10. 50
  11. 51
  12. 52

    Loss of C9orf72 decreases mTOR activation. by Janet Ugolino (3359054)

    Published 2016
    “…C9orf72-/- MEF cells show a decrease in p-S6K1 when compared with wild-type cells. …”
  13. 53
  14. 54
  15. 55
  16. 56
  17. 57
  18. 58

    Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

    Published 2016
    “…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”
  19. 59
  20. 60